Gan et al. launched a phase I clinical trial of the anti-EPHA2 DS-8895a antibody in patients with advanced EPHA2-expressing epithelial cancers, one of whom was diagnosed with NSCLC. The gene discussed is EPHA2; the disease is non-small cell lung carcinoma.